Illumina, headquartered in San Diego, develops life science tools for genetic analysis, employing 10,590 staff since its IPO in 2000. Its products span various applications, including oncology and agriculture.
Jacob Thaysen bought 6,500 shares of ILMN on 12 May at $82.66 per share, worth a total of $537K. They now own 77,540 ILMN shares, or a 9% holding increase.
📡️ Health Care
Insider Trades
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
